A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis - Trial NCT06295692
Access comprehensive clinical trial information for NCT06295692 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Pharmaceutical K.K. and is currently Recruiting. The study focuses on Generalized Pustular Psoriasis,Erythrodermic Psoriasis. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Janssen Pharmaceutical K.K.
Timeline & Enrollment
Phase 3
Feb 09, 2024
Dec 23, 2027
Primary Outcome
Percentage of Participants With Generalized Pustular Psoriasis (GPP) who Experience Treatment Success Based on Clinical Global Impression (CGI) Scale According to Japanese Dermatological Association (JDA) Total Score at Week 16,Percentage of Participants With Erythrodermic Psoriasis (EP) who Experience Treatment Success Based on CGI Scale at Week 16
Summary
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with
 generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06295692
Non-Device Trial